Shanghai Pharma x SPH-INNO x HKSTP co-incubation programme01LABS@Hong Kong facilitates the assessment of critical early-stage biotech initiatives originating from local universities or scientific research institutions in HK, esp. focusing on gene and cell therapy, autoimmune diseases, anti-aging, and other novel therapies. Empowering incubation and translational research with the ultimate goal of advancing the commercialization of fundamental scientific research right from the outset.

Drug Safety Testing Centre (DSC)To facilitate the translation of promising therapeutics and medical devices from the pre-clinical phase (toxicology, genotoxicity, toxicokinetics, safety pharmacology, reproductive toxicology, ADME) to the clinical stage. DSC fully supports the industry needs include Good Laboratory Practice - GLP (China NMPA, US FDA & OECD) & AAALAC.

HKCeND, building on the pioneering work of HKUST’s State Key Laboratory of Molecular Neuroscience, is one of the HKSAR InnoHK clusters, and aims to be the world’s leading research center focused on neurodegenerative diseases with the leadership of Prof. Nancy Ip x UCL x Stanford University with the goal of developing novel biomarkers and identifying therapeutic targets and systemic factors to treat neurodegenerative diseases and related technologies.

State Key Laboratory of Molecular Neuroscience at The Hong Kong University of Science and Technology (HKUST). Mainly focusing in neural development and function, as well as drug discovery for neurodegenerative diseases such as Alzheimer’s disease with the leadership of Prof. Nancy Ip.